Drugs used in obstetrics have a profound impact on the outcome of both the mother and the baby. The physiological changes of pregnancy alter the pharmacokinetics of drugs, and the placental barrier allows many medications to cross into the fetal circulation.

• First Trimester (Organogenesis): Drugs used during the first trimester can produce severe congenital malformations. The period of greatest risk is from the 3rd to the 11th week of pregnancy.
• Second and Third Trimesters: During this period, drugs can affect the growth and functional development of the fetus, or they can have direct toxic effects on fetal tissues.

The primary drugs used routinely or for specific conditions during pregnancy include nutritional supplements, antihypertensives, and diuretics.

• Preparation: Injection - 10ml vial (5mg/ml with 1.5% benzyl alcohol); Tablets - 0.4mg, 0.8mg, 1mg.
• Action: Stimulates normal erythropoiesis and nucleoprotein synthesis. Essential for fetal cellular division and DNA synthesis.
• Indications:
  • Prevention and treatment of megaloblastic or macrocytic anemia during pregnancy to prevent fetal damage.
  • Prevention of fetal neural tube defects (e.g., spina bifida, anencephaly).
• Contraindications: Untreated Vitamin B12 deficiency (can mask pernicious anemia).
• Adverse Effects: Abdominal cramps, diarrhea, rash, irritability, nausea, or bloating.
• Dosage & Route: 0.4mg (400mcg) OD orally. For parenteral use: 0.4 - 0.8mg IM or subcutaneously daily.
• Nursing Considerations: Patients with a history of fetal neural tube defects in a previous pregnancy should increase folic acid intake 1 month before and 3 months after conception (often up to 4-5mg daily). Patients with intestinal malabsorption may require parenteral administration.

• Preparation: Tablets (90mg, 200mg, 300mg, 325mg, 350mg). Each 100mg provides 33mg of elemental iron. Injection (Iron Sucrose): 20mg elemental iron/ml in 5ml and 10ml single-dose vials.
• Action: Provides elemental iron, an essential component in the formation of hemoglobin, preventing maternal and fetal hypoxia.
• Indications: Iron deficiency anemia; routine supplement during pregnancy.
• Contraindications: Primary hemolytic anemia, peptic ulcer disease, ulcerative colitis, repeated blood transfusions.
• Adverse Effects: Metallic taste, temporarily stained teeth (liquid forms), nausea or vomiting, GI irritation, black stools (harmless but should be explained to the patient).
• Dosage & Route: Oral: 30mg OD. IV/IM: Dose is 15mg/kg body weight (max 1000mg in a single injection), given deep IM or diluted in 100ml of NS for slow IV infusion.
• Nursing Considerations:
  • Advise patient to avoid taking the tablet with milk or antacids (calcium decreases absorption). Vitamin C (citrus juice) enhances absorption.
  • Caution the patient not to crush the tablet.
  • Caution not to blindly substitute one iron salt for another, as the amount of elemental iron varies significantly.
  • Advise the patient to report severe constipation or changes in stool color.

• Preparation: Tablets (250mg, 500mg). Each tablet typically contains 211mg (10.6 mEq) of elemental calcium.
• Action: Replaces calcium stores depleted by fetal bone development and maintains maternal calcium levels.
• Indications: Calcium supplement during pregnancy to prevent maternal osteopenia and fetal skeletal issues.
• Contraindications: Cancer patients with bone metastasis, hypercalcemia, hypophosphatemia, renal calculi.
• Adverse Effects: Headache, irritability, hypercalcemia, chalky taste, nausea, or vomiting.
• Dosage & Route: 500mg OD orally.
• Nursing Considerations: Advise patient to take oral calcium 1 to 1.5 hours after meals if GI upset occurs. Monitor calcium levels closely if the patient has mild renal impairment. Report abdominal pain, nausea, or vomiting.

Hypertensive disorders of pregnancy (e.g., pre-eclampsia) require careful pharmacological management to prevent stroke or eclampsia without harming the fetus.

1. Labetalol Hydrochloride (Alpha and Beta Blocker):
   • Preparation: Tablets (100mg, 200mg, 300mg); Injection (5mg/ml in 20ml vial).
   • Action: Reduces peripheral vascular resistance as a result of combined alpha and beta blockade.
   • Indications: Chronic hypertension, Hypertensive emergencies (severe pre-eclampsia).
   • Contraindications: Hypersensitivity, bronchial asthma, hepatic/heart failure, prolonged hypotension, severe bradycardia.
   • Adverse Effects: Dizziness, fatigue, nausea, vomiting, headache, vertigo.
   • Dosage: Oral: 50mg or 100mg OD/BD. IV: 20mg IV bolus over 2 mins; wait 10 min, if no response give 40mg slow bolus (up to 300mg total).
   • Nursing: Keep patient supine for 3 hours after IV infusion. Monitor BP frequently. In diabetic patients, monitor glucose closely (beta-blockers can mask hypoglycemia). Advise slow position changes to minimize dizziness.
2. Nifedipine (Calcium Channel Blocker):
   • Preparation: Capsules (10mg, 20mg); Tablets (20mg, 30mg, 60mg, 90mg).
   • Action: Inhibits calcium ion influx across cardiac and smooth muscle cells, decreasing contractility and oxygen demand. Dilates coronary arteries and arterioles.
   • Indications: Hypertension, classic chronic stable angina pectoris (also used off-label as a tocolytic).
   • Contraindications: Heart failure, hypotension, severe GI narrowing.
   • Adverse Effects: Dizziness, syncope, heart failure, muscle cramps, peripheral edema.
   • Dosage: 5-20mg OD orally.
   • Nursing: Monitor BP and HR regularly. Advise the patient strictly to avoid grapefruit juice (inhibits metabolism, causing toxicity). Watch for signs of heart failure.
3. Methyldopa (Centrally Acting Alpha Blocker):
   • Preparation: Tablets (250mg, 500mg); Injection (50mg/ml).
   • Action: Inhibits the central vasomotor center, decreasing sympathetic outflow to the heart, kidneys, and peripheral vasculature.
   • Indications: Chronic hypertension in pregnancy, hypertensive crisis.
   • Contraindications: Hepatic disease or liver cirrhosis, lactating mothers (can cause severe depression).
   • Adverse Effects: Decreased mental acuity, sedation, headache, depression, bradycardia, hepatic necrosis, hepatitis.
   • Dosage: 250mg BD or TDS (max 2g daily).
   • Nursing: Monitor BP regularly. Monitor patient's Coombs test result (can cause positive direct Coombs and hemolytic anemia). Report involuntary movements. Weigh daily and notify provider if weight gain exceeds 2 lbs/week.
4. Hydralazine Hydrochloride (Vasodilator):
   • Preparation: Tablets (10mg, 25mg, 50mg, 100mg); Injection (20mg/ml).
   • Action: Direct-acting peripheral vasodilator that relaxes arteriolar smooth muscle.
   • Indications: Severe essential hypertension, hypertensive emergencies in pre-eclampsia.
   • Contraindications: Coronary artery disease, rheumatic heart disease, stroke, severe renal impairment.
   • Adverse Effects: Neutropenia, leukopenia, thrombocytopenia, orthostatic hypotension.
   • Dosage: 25mg BD (increase to 50mg BD if needed). IV: 5mg diluted in 10ml of NS given as a slow IV push.
   • Nursing: Monitor BP, pulse, and weight frequently. Monitor for muscle/joint pain, fever, or sore throat (drug-induced lupus syndrome). Take with food to increase absorption.

Diuretics are rarely used routinely in pregnancy due to the risk of decreasing placental perfusion, but they are indicated in specific, life-threatening fluid overload states.

• Indications during pregnancy: Pregnancy-induced hypertension (PIH) with massive edema, Eclampsia with pulmonary edema, severe anemia in pregnancy with heart failure, prior to blood transfusion in severe anemia, or as an adjunct to certain antihypertensive drugs.
• Preparation: Tablets (20mg, 40mg, 80mg, 500mg); Injection (10mg/ml).
• Action: Inhibits sodium and chloride reabsorption at the proximal/distal tubules and the ascending Loop of Henle, causing profound diuresis.
• Contraindications: Anuria, hepatic cirrhosis, allergy to sulfonamides.
• Adverse Effects: Maternal: Weakness, fatigue, muscle cramps, severe hypokalemia. Fetal: May cause decreased placental perfusion leading to fetal compromise; fetal hyponatremia.
• Dosage: 40mg tablet daily following breakfast. In acute conditions (pulmonary edema), administered parenterally 40-120mg daily.
• Nursing Considerations: Monitor weight, BP, and pulse routinely. Strict strict I/O charting. Watch for signs of hypokalemia (muscle weakness, ECG changes). Administer in the morning to prevent nocturia. Monitor uric acid if the patient has gout. Protect medication from direct sunlight to prevent photosensitivity reactions.

These drugs inhibit uterine contractions and are used to prolong pregnancy. In women who develop premature uterine contractions, tocolytic drugs are administered (along with absolute bed rest and sedation) in an attempt to arrest preterm labor and allow time for fetal lung maturation (usually via maternal corticosteroid administration).

• Preparation: Tablets (10mg); Injection (10mg/ml).
• Action: Acts directly on vascular smooth muscle, causes cardiac stimulation, and profound uterine relaxation (beta-adrenergic agonist properties). Dilates veins and arteries, increasing blood flow to certain parts of the body.
• Indications: Prevention of preterm labor, inhibition of uterine contractions.
• Contraindications: Hypersensitivity, postpartum state, active maternal bleeding.
• Adverse Effects: Maternal hypotension, tachycardia, nausea/vomiting, pulmonary edema, cardiac arrhythmias, hyperglycemia, or hypokalemia.
• Dosage: Initial IV drip: 100mg in 5% Dextrose at a rate of 0.2mcg/minute. Continue at least 2 hours after contractions cease. Maintenance: IM 10mg 6-hourly for 24 hours, or orally 10mg 6-8 hourly.
• Nursing Considerations: Assess BP and pulse constantly during treatment. Take BP lying and standing (orthostatic hypotension is highly common). Monitor intensity and length of uterine contractions and continuous Fetal Heart Sound (FHS) monitoring. Advise slow position changes to prevent fainting.

• Preparation: Injection (5ml ampoule = 10mg/ml); Tablets (10mg).
• Action: A selective Beta-2 adrenergic agonist that acts directly on vascular smooth muscle to cause uterine relaxation.
• Indications: Prevention and arrest of preterm labor.
• Contraindications: Hypersensitivity, Eclampsia/severe pre-eclampsia, maternal hypertension, dysrhythmias, maternal hyperthyroidism.
• Adverse Effects: Hyperglycemia, headache, restlessness/sweating, chills/drowsiness, nausea/vomiting, altered maternal & fetal heart tones, and palpitations.
• Dosage: Initial IV drip: 100mg in 5% Dextrose at 0.1mg/min, gradually increased by 0.05mg/min. Continue for at least 2 hours after contractions cease. Maintenance: Tablet 10mg 6-8 hourly (PO 10mg given 30 mins before stopping IV, then 10mg q2h for 24h, then 10-20mg q4h, not to exceed 120mg/day).
• Nursing Considerations:
  • Assess maternal and fetal heart tones continuously.
  • Monitor fluid intake strictly to prevent fluid overload and pulmonary edema; discontinue if dyspnea or crackles occur.
  • Administer only clear solutions via an infusion pump for precise titration.
  • Position the patient in the left lateral recumbent position to decrease hypotension and increase renal/placental blood flow.

Drugs used in labor can be grouped according to the effect they have on the uterus and maternal nervous system: Uterine Stimulants (Oxytocics/Abortifacients), Analgesics, Anticonvulsants, and Anticoagulants.

Oxytocics are drugs that have the power to excite contractions of the uterine muscles. They are used to assist/augment labor, induce abortion (abortifacients), or prevent/treat postpartum hemorrhage.

• Classification: Class B controlled drug; Medical class: Oxytocic. It is an octapeptide synthesized in the hypothalamus and stored in the posterior pituitary.
• Preparation: Sterile solution for injection. Syntocinon (5 units/ml), Pitocin (10 units/ml). Oxytocin nasal solution (40 units/ml).
• Action: Acts directly on myofibrils producing powerful, rhythmic uterine contractions. Also stimulates milk ejection (let-down reflex) by contracting myoepithelial cells in the breasts.
• Pharmacokinetics: Absorption is immediate following IV injection. Distributed throughout extracellular fluid; small amounts cross the placenta. Metabolized rapidly in liver/kidneys and excreted in urine.
• Indications:
  • Pregnancy/Labor: Induction of labor, augmentation of labor (hypotonic uterine contractions), oxytocin challenge test.
  • Abortions: To induce abortion, expedite expulsion of hydatidiform mole, or stop bleeding following evacuation. Cases of Intra-Uterine Fetal Death (IUFD).
  • Postpartum: Active management of 3rd stage of labor, prevent and treat postpartum hemorrhage (PPH), initiate milk let-down in breast engorgement.
• Contraindications: Hypertonic uterine action, fetal or maternal distress, grand multipara (risk of rupture), multiple pregnancy, contracted pelvis / cephalo-pelvic disproportion (CPD), malpresentation (breech, brow), history of LSCS or previous uterine scar, obstructed labor.
• Adverse Effects: Uterine rupture (most severe), fetal bradycardia, hypoxia and anoxia leading to birth asphyxia, maternal hypotension, neonatal jaundice. High doses given in electrolyte-free fluids can cause water retention and severe water intoxication (due to ADH-like effect).
• Dosage & Route:
  • Induction/Augmentation: Controlled IV infusion (e.g., 5-10 IU in 500ml/1L of RL or 5% Dextrose), initially at a very slow rate (e.g., 2-5 drops/min) titrated to contraction pattern.
  • PPH Prevention: 5-10 IU slow IV or deep IM after delivery of the anterior shoulder or placenta.
• Nursing Considerations: Assess strict Intake/Output ratio (water intoxication risk). Monitor continuous fetal heart rate and maternal BP. Evaluate the length and duration of contractions; immediately stop infusion and notify physician if contractions last >60-90 seconds (hyperstimulation) or if fetal deceleration occurs. Ensure a crash cart is available.

• Preparation: Natural or semi-synthetic. Ergometrine (0.25mg/0.5mg ampoules, 0.5mg tablets); Methergine (0.2mg ampoules, 0.5mg tablets).
• Action: Acts directly on the myometrium to produce tetanic (sustained) uterine contractions, which rapidly compresses torn blood vessels at the placental site, decreasing bleeding.
• Indications: Therapeutic: To stop atonic uterine bleeding following delivery, abortion, or mole expulsion. Prophylactic: Against excessive hemorrhage, administered after delivery of the anterior shoulder or following delivery.
• Contraindications: Suspected plural (multiple) pregnancy (do not give until the last twin is out), organic cardiac disease, severe pre-eclampsia, eclampsia, or hypertension.
• Adverse Effects: Sudden rise in BP due to potent vasoconstriction. Nausea, vomiting, headache. Prolonged use in puerperium may interfere with lactation (decreases prolactin concentration).
• Dosage & Route: 0.2mg IM for active management of 3rd stage. For severe PPH, 1 ampoule given slowly IV over 60 seconds. For excessive lochia/subinvolution: 1 tablet (0.125mg) TDS for 3 days.
• Nursing Considerations: NOTE: As the drug produces tetanic contractions, it should NEVER be used for induction of labor or abortion. Assess BP before administration. Have emergency hypertensive drugs available.

• Preparation: A combination ampoule containing Ergometrine 0.5mg + Oxytocin (Syntocinon) 5 IU in 1 ml.
• Action: Combines the rapid onset of oxytocin (2-3 mins) with the sustained tetanic action of ergometrine (hours).
• Indications: Active management of the third stage of labor; severe PPH.
• Contraindications: Same as Ergometrine (hypertension, severe pre-eclampsia, cardiac disease, undiagnosed 2nd twin).
• Adverse Effects: Retained placenta (if given too early), retained 2nd twin (fatal IUFD if trapped), severe hypertension, dyspnea.
• Nursing Considerations: Syntometrine should always be administered IM, never as an IV bolus due to the severe hypertensive spike risk.

Prostaglandins are synthesized from arachidonic acid. They have powerful oxytocic effects and uniquely sensitize the myometrium to oxytocin while actively softening (ripening) the cervix.

• Preparations:
  • PGE1 (Misoprostol): Tablets (100mcg, 200mcg, 600mcg).
  • PGE2 (Dinoprostone / Prostin E2 / Cervidil): Tablets (0.5mg); Vaginal Gel (0.5mg in 2.5ml syringe); Vaginal insert/pessary.
  • PGF2-alpha (Dinoprost / Carboprost): Injection (125mcg, 250mcg).
• Action: PGF2-alpha acts predominantly on the myometrium (intense contractions). PGE2 and PGE1 act mainly on the cervix (breakdown of collagen, increasing elasticity) and also stimulate contractions.
• Indications:
  • Cervical ripening prior to induction of labor.
  • Induction of abortion during 2nd trimester & expulsion of hydatidiform mole / IUFD.
  • To stop severe refractory atonic PPH (Misoprostol 600-800mcg PR/SL, or Carboprost IM).
• Contraindications: Hypersensitivity, placenta previa (grade 3/4), multiparous mothers (high risk of rupture), previous Caesarean section (for Misoprostol labor induction), cephalopelvic disproportion, uterine fibroids, pelvic inflammatory disease (PID).
• Adverse Effects: Headache, dizziness, fever, severe shivering/chills, explosive diarrhea, nausea, vomiting, hypotension, joint swelling. Major risk: Uterine hyperstimulation and rupture.
• Dosage & Route (Misoprostol): For induction: 25-50mcg vaginally or orally every 4 hours. For PPH: 600mcg-800mcg rectally or sublingually. (Note: The user text mentions 100mcg q12h for induction, but standard WHO/ACOG guidelines mandate 25mcg for live viable term fetuses to prevent hyperstimulation).
• Nursing Considerations:
  • Assess vital signs, respiratory rhythm, vaginal discharge.
  • Administer antiemetic/antidiarrheal preparations prior to giving Carboprost.
  • For Dinoprostone gel/suppository: Warm the package under warm water. Advise patient to remain supine for 10-15 minutes after vaginal insertion.
  • Evaluate length and duration of contractions; monitor for fetal distress and maternal fever/chills.

• Classification: Cervical spasmolytic / Anticholinergic.
• Preparation: Injection (1 ampoule = 8mg/ml).
• Action: It is both a central and peripheral antimuscarinic agent. It acts as a competitive inhibitor of acetylcholine at the muscarinic receptor, inducing smooth muscle relaxation and facilitating cervical dilation.
• Indications: To accelerate cervical dilatation in the active first stage of labor. Symptomatic relief of GI tract and ureteric colic.
• Contraindications: Paralytic ileus, Myasthenia Gravis, severe hypertension, closed-angle glaucoma, severe cardiovascular disorders.
• Adverse Effects: Dryness of mouth, intense thirst, dilatation of pupils (blurred vision), palpitations, tachycardia, giddiness.
• Dosage: 8mg deep IM or slow IV. May be repeated after 4 hours if necessary.
• Nursing Considerations: Advise the patient to report any blurred vision or severe dry mouth. Instruct the patient to get up from the bed carefully and slowly due to giddiness and orthostatic risks. Monitor maternal and fetal heart rate (can cause maternal tachycardia).

• Preparation: Injection (50mg/ml); Tablets (50mg, 100mg, 200mg).
• Action: Binds to mu-opioid receptors and weakly inhibits the reuptake of norepinephrine and serotonin. Provides centrally acting analgesia.
• Indications: Moderate to severe pain relief. Safe to be given during labor as it does not cause severe depression to the fetal respiratory center (unlike pethidine or morphine), hence safer for the baby.
• Contraindications: Breastfeeding mothers (long-term), hypersensitivity, hepatic impairment, increased Intracranial Pressure (ICP).
• Adverse Effects: Dizziness, headache, malaise, hypertonia, nausea, vomiting.
• Dosage: 50 to 100mg IM 6-hourly or as required.
• Nursing Considerations: Monitor patient cardiovascular and respiratory status. Monitor patients at risk for seizures (tramadol lowers seizure threshold). Monitor bowel and bladder function (urinary retention).

• Preparation: Injection: 1 ampoule = 2ml containing 1gm MgSO4 (typically available as 20% or 50% solutions).
• Action: Decreases acetylcholine release at motor nerve terminals, acting as a profound anticonvulsant and reducing neuromuscular irritability. It decreases intracranial edema and induces mild diuresis. Its peripheral vasodilatation effect improves uterine blood supply. It also acts as a CNS and uterine muscle depressant (tocolytic).
• Indications:
  • Drug of choice for lowering seizure threshold in severe pre-eclampsia and eclampsia.
  • Used in preterm labor to decrease uterine activity (Neuroprotection for preterm fetus).
• Contraindications: Heart block, severe myocardial damage, impaired renal function (excreted solely by kidneys), pregnant women actively progressing in normal labor (will arrest contractions).
• Adverse Effects:
  • Maternal: Severe CNS depression, flushing, sweating, muscular paresis, respiratory paralysis, circulatory collapse.
  • Fetal: Tachycardia, hypoglycemia, hypotonia, respiratory depression at birth.
• Dosage & Route:
  • Seizure Control (Pritchard Regimen): Loading dose: 4g IV slowly (20% solution over 5-10 mins), followed immediately by 10g IM (5g in each buttock of 50% solution). Maintenance: 5g IM 4-hourly into alternate buttocks.
  • Tocolytic effect: 4g IV slowly over 10 mins, followed by an IV drip of 1-2g/hr.
  • Therapeutic Serum Level: 4 - 7 mEq/L.
• Nursing Considerations (Toxicity Monitoring is Critical!):
  • Assess vital signs 15 mins after IV dose. Use an infusion pump.
  • Monitor the 4 strict criteria before administering any repeat dose:
    1. Reflexes: Patellar (knee-jerk) reflex MUST be present.
    2. Respirations: Must be > 12 breaths/minute.
    3. Urine Output: Must be > 30 ml/hr (or 100ml in 4 hours).
    4. Antidote: 10% Calcium Gluconate (10ml IV) MUST be readily available at the bedside to treat magnesium toxicity.
  • Provide seizure precautions (padded side rails, decreased stimuli).
  • Discontinue infusion immediately in the event of severe hypotonia, mental confusion, lethargy, or fetal distress.

During the postpartum period (puerperium), maternal care focuses on recovery, pain relief, and initiating or suppressing lactation. Standard supplements like Iron, Folic Acid, and Calcium are continued to replenish depleted maternal stores.

• Preparation: Tablets (500mg); Suppository; Oral Solution; IV infusion.
• Action: Produces central analgesia by inhibiting prostaglandin synthesis in the CNS and blocking pain impulse generation.
• Indications: Mild to moderate postpartum pain (episiotomy, afterpains), fever.
• Contraindications: Severe liver disease, hypersensitivity.
• Adverse Effects: Generally safe, but overdose causes severe hepatotoxicity. Rare: neutropenia, hemolytic anemia, hypoglycemia, urticaria.
• Dosage: 500mg to 1000mg orally thrice or four times a day (max 4g/day).
• Nursing Considerations: Advise the patient not to exceed the prescribed dose. Warn about taking concurrent OTC cold medications that also contain acetaminophen. Take after meals to prevent GI upset.

NURSING ALERT: While historically used to dry up breast milk, the FDA and global health authorities have withdrawn the approval of Bromocriptine for routine lactation suppression due to severe, life-threatening complications (maternal stroke, seizures, myocardial infarction, and death). It is now restricted strictly to medical conditions like prolactinomas or severe psychiatric illness where lactation is absolutely contraindicated, and safer alternatives are unavailable. Conservative management (firm bra, ice packs, analgesics) or Cabergoline are preferred.

• Preparation: Tablets (0.8mg, 2.5mg).
• Action: A potent dopamine receptor agonist that directly blocks the release of prolactin from the anterior pituitary gland.
• Indications: Medical suppression of lactation (e.g., stillbirth, neonatal death, severe breast abscess, HIV mothers where formula is safe), Pregnancy with prolactinoma, Infertility, Amenorrhea.
• Adverse Effects: Severe dizziness or lightheadedness (orthostatic hypotension), confusion, hallucinations, severe paradoxical hypertension, seizures, myocardial infarction.
• Dosage: 2.5mg tablet orally once a day (if strictly indicated).
• Nursing Considerations: Monitor patient for severe adverse cardiovascular reactions. Assess orthostatic vital signs before initiation. Instruct patient to take the drug with a meal. Warn the patient: The drug rapidly restores fertility; it may lead to early postpartum conception. Advise barrier contraception and test for pregnancy if menses do not resume normally.

• Rationale: At birth, the newborn's sterile colon lacks the normal bacterial flora necessary for synthesizing fat-soluble Vitamin K. Therefore, newborns have a transient, dangerous decrease in Prothrombin and clotting factors (II, VII, IX, X) during the first 5 to 8 days of life, predisposing them to Hemorrhagic Disease of the Newborn.
• Preparation: Injection (2ml vial = 2mg/ml or 1mg/0.5ml pediatric ampoules).
• Action: Promotes the hepatic formation of clotting factors II, VII, IX, and X.
• Indications: Routine prophylaxis to prevent neonatal bleeding problems.
• Adverse Effects: Pain and edema at the injection site. Allergic reactions (urticaria, rash). Rare: Hyperbilirubinemia (especially in premature infants given high doses).
• Dosage & Route: 0.5mg to 1mg IM administered into the vastus lateralis muscle within 1 hour of birth.
• Nursing Considerations: Meticulously document the administration to prevent accidental double-dosing. Observe the injection site for local inflammation. Observe the infant for bleeding (usually peaks on the 2nd or 3rd day if unprotected) and monitor for physiological jaundice.

1. Early Embryogenesis (Days 1-14): Drugs taken by the mother reach the conceptus through tubal/uterine secretions by diffusion. The "All or Nothing" rule applies: the harmful effect on the blastocyst is usually death/miscarriage. If it survives, there is a lower chance of specific organ anomalies but high risk of overall disruption.
2. Organogenesis (2nd - 12th week): The period of maximum vulnerability. Drugs crossing the placenta can cause serious, irreversible gross congenital malformations (Teratogenesis).
3. Second & Third Trimester: Transfer of drugs takes place rapidly through the utero-placental circulation.
   • Maternal physiological hemodilution lowers serum albumin concentration. Because the albumin binding capacity is decreased, more free (unbound, active) drug is available for placental transfer.
   • Increased utero-placental blood flow, increased placental surface area, and decreased thickness of the placental membrane late in pregnancy dramatically increase drug transfer.

Rule of Thumb: Fetotoxic or teratogenic drugs are prescribed ONLY when the maternal benefits clearly outweigh the potential fetal risks. Minimum therapeutic dosage is used for the shortest possible duration after mandatory counseling.

Maternal drug intake can have adverse effects on lactation itself (suppressing supply) and on the baby via transmission in breast milk. The transfer of drugs into breast milk depends on several pharmacologic factors:

• Chemical properties & Molecular weight: Small molecules pass easily.
• Degree of protein binding: Highly protein-bound drugs stay in maternal plasma; low protein binding means higher milk concentration.
• Lipid solubility: Highly lipid-soluble drugs easily cross into the fat-rich breast milk.
• Ionic dissociation & Tissue pH: Breast milk is slightly more acidic than plasma (pH 7.2 vs 7.4). Weak basic drugs become ionized and trapped in milk ("ion trapping").
• Drug concentration gradient & Exposure time.

• Bromides: Rash, severe drowsiness, poor feeding in the neonate.
• Iodides: Risk of neonatal hypothyroidism.
• Chloramphenicol: Bone marrow toxicity and "Gray Baby Syndrome".
• Metronidazole: Anorexia, blood dyscrasias, weakness, neurotoxic disorders (pump and dump recommended for 12-24 hours after a stat dose).
• Anticoagulants (Warfarin/Heparin): Depending on the type, can pose a risk of hemorrhagic tendency in the fragile newborn (Heparin is generally safe as it does not cross into milk; Warfarin is highly protein bound but must be monitored).
• Isoniazid (INH): Anti-DNA activity and risk of hepatotoxicity.
• Diazepam, Opiates, Phenobarbitone: Profound sedation effect, causing poor sucking reflex, lethargy, and failure to thrive in the infant.
• Oral Contraceptive Pills (Estrogen-containing): Severe suppression of lactation and milk volume.
• Bromocriptine / Ergot derivatives: Complete suppression of lactation.

• No drug should be administered to a woman during pregnancy, labor, and birth unless the woman is fully informed of the known risks and the relevant areas of uncertainty regarding the effects of the drug on the physiologic and neurologic development of her baby.
• The drugs that are used daily in obstetrics can have a huge impact on the outcome of both mother and child.
• Therefore, obstetric providers and nurses need to have a very clear, evidence-based understanding of the mechanisms of action, doses, maternal-fetal side effects, and antidotes of the most commonly used drugs.

• Jacob, Annamma. A Comprehensive Textbook of Midwifery & Gynecological Nursing (3rd Edition). Jaypee Brothers Medical Publishers (P) Ltd, pp. 604-619.
• Dutta, D.C. Textbook of Obstetrics (7th Edition). New Central Book Agency (P) Ltd, p. 666.
• Debdas, A.K. Drug Handbook in Obstetrics (3rd Edition). Jaypee Brothers Medical Publishers, New Delhi.
• Wolters Kluwer. Nursing Drug Handbook (32nd Edition). Lippincott Williams & Wilkins, London.
• World Health Organization (WHO) / ACOG Guidelines on the Management of Postpartum Haemorrhage and Induction of Labour.
• FDA Drug Safety Communications regarding Bromocriptine for Lactation Suppression.